Evidence map›Paper›PMID 37229647›Full record

ArticleJournal of chemical information and modeling2023

Fragment Merging Using a Graph Database Samples Different Catalogue Space than Similarity Search.

Stephanie Wills, Ruben Sanchez-Garcia, Tim Dudgeon, Stephen D Roughley, Andy Merritt, Roderick E Hubbard, James Davidson, Frank von Delft, Charlotte M Deane

Abstract read
In one paragraph

Article in Journal of chemical information and modeling, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Structural Chemistry of Helicase Inhibition.Journal of medicinal chemistry · 2025
    Review
  8. Article
  9. Article
  10. Molecular similarity: Theory, applications, and perspectives.Artificial intelligence chemistry · 2024
    Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Stephanie WillsDepartment of Statistics, University of Oxford, Oxford OX1 3LB, United Kingdom.ORCID 0000-0003-4536-1910
Ruben Sanchez-GarciaDepartment of Statistics, University of Oxford, Oxford OX1 3LB, United Kingdom.ORCID 0000-0001-6156-3542
Tim DudgeonInformatics Matters, Ltd., Perch Coworking, Franklins House, Bicester OX26 6JU, United Kingdom.
Stephen D RoughleyVernalis (R&D) Limited, Granta Park, Great Abington, Cambridge CB21 6GB, United Kingdom.ORCID 0000-0003-0683-5693
Andy MerrittLifeArc, Lynton House, 7-12 Tavistock Square, London WC1H 9LT, United Kingdom.ORCID 0000-0002-0787-1648
Roderick E HubbardVernalis (R&D) Limited, Granta Park, Great Abington, Cambridge CB21 6GB, United Kingdom.ORCID 0000-0002-8233-7461
James DavidsonVernalis (R&D) Limited, Granta Park, Great Abington, Cambridge CB21 6GB, United Kingdom.ORCID 0000-0002-8301-1607
Frank von DelftCentre for Medicines Discovery, University of Oxford, Oxford OX3 7DQ, United Kingdom.ORCID 0000-0003-0378-0017
Charlotte M DeaneDepartment of Statistics, University of Oxford, Oxford OX1 3LB, United Kingdom.ORCID 0000-0003-1388-2252

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fragment merging is a promising approach to progressing fragments directly to on-scale potency: each designed compound incorporates the structural motifs of overlapping fragments in a way that ensures compounds recapitulate multiple high-quality interactions. Searching commercial catalogues provides one useful way to quickly and cheaply identify such merges and circumvents the challenge of synthetic accessibility, provided they can be readily identified. Here, we demonstrate that the Fragment Network, a graph database that provides a novel way to explore the chemical space surrounding fragment hits, is well-suited to this challenge. We use an iteration of the database containing >120 million catalogue compounds to find fragment merges for four crystallographic screening campaigns and contrast the results with a traditional fingerprint-based similarity search. The two approaches identify complementary sets of merges that recapitulate the observed fragment-protein interactions but lie in different regions of chemical space. We further show our methodology is an effective route to achieving on-scale potency by retrospective analyses for two different targets; in analyses of public COVID Moonshot and

Indexed as

COVID-19Mycobacterium tuberculosisCrystallographyDatabases, FactualHumansRetrospective Studies

Identifiers

PMID37229647
PMCPMC10268959

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.